Publications by authors named "Mary Ellen Simcox"

Claim this Profile
C
CUE-101, a Novel E7-pHLA-IL2-Fc Fusion Protein, Enhances Tumor Antigen-Specific T-Cell Activation for the Treatment of HPV16-Driven Malignancies.
Steven N Quayle, Natasha Girgis, Dharma R Thapa, Zohra Merazga, Melissa M Kemp, Mary Ellen Simcox

Clin Cancer Res· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.
Hong Yang, Brian Higgins, Kenneth Kolinsky, Kathryn Packman, William D Bradley, Mary Ellen Simcox

Cancer Res· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation.
Fei Su, William D Bradley, Qiongqing Wang, Hong Yang, Lizhong Xu, Mary Ellen Simcox

Cancer Res· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models.
Hong Yang, Brian Higgins, Kenneth Kolinsky, Kathryn Packman, Zenaida Go, Mary Ellen Simcox

Cancer Res· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A new series of potent oxindole inhibitors of CDK2.
Kin-Chun Luk, Mary Ellen Simcox, Andy Schutt, Karen Rowan, Thelma Thompson

Bioorg Med Chem Lett· February 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
3
3,5,6-Trisubstituted naphthostyrils as CDK2 inhibitors.
Jin-Jun Liu, Apostolos Dermatakis, Christine Lukacs, Fred Konzelmann, Yi Chen, Mary Ellen Simcox

Bioorg Med Chem Lett· August 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis